These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

355 related items for PubMed ID: 31542260

  • 1. Antigenicity and immunogenicity of unique prefusion-mimic F proteins presented on enveloped virus-like particles.
    Kwon YM, Lee Y, Kim KH, Jung YJ, Li Z, Jeeva S, Lee S, Moore ML, Kang SM.
    Vaccine; 2019 Oct 16; 37(44):6656-6664. PubMed ID: 31542260
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
    Liang B, Ngwuta JO, Herbert R, Swerczek J, Dorward DW, Amaro-Carambot E, Mackow N, Kabatova B, Lingemann M, Surman S, Yang L, Chen M, Moin SM, Kumar A, McLellan JS, Kwong PD, Graham BS, Schaap-Nutt A, Collins PL, Munir S.
    J Virol; 2016 Nov 01; 90(21):10022-10038. PubMed ID: 27581977
    [Abstract] [Full Text] [Related]

  • 5. Virus-like particle vaccines containing F or F and G proteins confer protection against respiratory syncytial virus without pulmonary inflammation in cotton rats.
    Hwang HS, Kim KH, Lee Y, Lee YT, Ko EJ, Park S, Lee JS, Lee BC, Kwon YM, Moore ML, Kang SM.
    Hum Vaccin Immunother; 2017 May 04; 13(5):1031-1039. PubMed ID: 28129031
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection.
    Patel N, Massare MJ, Tian JH, Guebre-Xabier M, Lu H, Zhou H, Maynard E, Scott D, Ellingsworth L, Glenn G, Smith G.
    Vaccine; 2019 Sep 24; 37(41):6112-6124. PubMed ID: 31416644
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.
    Liu X, Liang B, Ngwuta J, Liu X, Surman S, Lingemann M, Kwong PD, Graham BS, Collins PL, Munir S.
    J Virol; 2017 Nov 15; 91(22):. PubMed ID: 28835504
    [Abstract] [Full Text] [Related]

  • 11. Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.
    Cimica V, Boigard H, Bhatia B, Fallon JT, Alimova A, Gottlieb P, Galarza JM.
    Clin Vaccine Immunol; 2016 Jun 15; 23(6):451-9. PubMed ID: 27030590
    [Abstract] [Full Text] [Related]

  • 12. Additive protection induced by mixed virus-like particles presenting respiratory syncytial virus fusion or attachment glycoproteins.
    Lee S, Quan FS, Kwon Y, Sakamoto K, Kang SM, Compans RW, Moore ML.
    Antiviral Res; 2014 Nov 15; 111():129-35. PubMed ID: 25239522
    [Abstract] [Full Text] [Related]

  • 13. VLPs generated by the fusion of RSV-F or hMPV-F glycoprotein to HIV-Gag show improved immunogenicity and neutralizing response in mice.
    Trinité B, Durr E, Pons-Grífols A, O'Donnell G, Aguilar-Gurrieri C, Rodriguez S, Urrea V, Tarrés F, Mane J, Ortiz R, Rovirosa C, Carrillo J, Clotet B, Zhang L, Blanco J.
    Vaccine; 2024 May 31; 42(15):3474-3485. PubMed ID: 38641492
    [Abstract] [Full Text] [Related]

  • 14. A single intranasal administration of virus-like particle vaccine induces an efficient protection for mice against human respiratory syncytial virus.
    Jiao YY, Fu YH, Yan YF, Hua Y, Ma Y, Zhang XJ, Song JD, Peng XL, Huang J, Hong T, He JS.
    Antiviral Res; 2017 Aug 31; 144():57-69. PubMed ID: 28529001
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Modification of the respiratory syncytial virus f protein in virus-like particles impacts generation of B cell memory.
    Schmidt MR, McGinnes-Cullen LW, Kenward SA, Willems KN, Woodland RT, Morrison TG.
    J Virol; 2014 Sep 01; 88(17):10165-76. PubMed ID: 24965456
    [Abstract] [Full Text] [Related]

  • 17. Murine immune responses to virus-like particle-associated pre- and postfusion forms of the respiratory syncytial virus F protein.
    McGinnes Cullen L, Schmidt MR, Kenward SA, Woodland RT, Morrison TG.
    J Virol; 2015 Jul 01; 89(13):6835-47. PubMed ID: 25903340
    [Abstract] [Full Text] [Related]

  • 18. Improved Prefusion Stability, Optimized Codon Usage, and Augmented Virion Packaging Enhance the Immunogenicity of Respiratory Syncytial Virus Fusion Protein in a Vectored-Vaccine Candidate.
    Liang B, Ngwuta JO, Surman S, Kabatova B, Liu X, Lingemann M, Liu X, Yang L, Herbert R, Swerczek J, Chen M, Moin SM, Kumar A, McLellan JS, Kwong PD, Graham BS, Collins PL, Munir S.
    J Virol; 2017 Aug 01; 91(15):. PubMed ID: 28539444
    [Abstract] [Full Text] [Related]

  • 19. Parainfluenza Virus 5 Expressing Wild-Type or Prefusion Respiratory Syncytial Virus (RSV) Fusion Protein Protects Mice and Cotton Rats from RSV Challenge.
    Phan SI, Zengel JR, Wei H, Li Z, Wang D, He B.
    J Virol; 2017 Oct 01; 91(19):. PubMed ID: 28747496
    [Abstract] [Full Text] [Related]

  • 20. A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles.
    Rigter A, Widjaja I, Versantvoort H, Coenjaerts FE, van Roosmalen M, Leenhouts K, Rottier PJ, Haijema BJ, de Haan CA.
    PLoS One; 2013 Oct 01; 8(8):e71072. PubMed ID: 23951084
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.